GABC vs NVCR
GABC: A regional financial holding company serving communities in Indiana, Kentucky, and Ohio with retail/commercial banking and wealth management services. NVCR: Novocure is a medical device company pioneering Tumor Treating Fields (TTFields) technology to treat aggressive solid tumor cancers by disrupting cancer cell division with electric fields.
Side-by-side fundamentals
| Metric | GABC | NVCR | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $48.95 | $13.15 | |
| Market cap | $1.8B | $1.5B | |
| P/E as of 2026-10-30 | 12.88 | n/a | |
| PEG as of 2026-10-30, 3-year EPS CAGR to FY2025 | 3.96 | n/a | |
| Net margin FY2025, SEC XBRL | +23.1% | -20.8% | GABC higher |
| Gross margin FY2025, SEC XBRL | n/a | +74.5% | |
| Operating margin FY2025, SEC XBRL | n/a | -23.5% | |
| ROE FY2025, SEC XBRL | +9.7% | -40.0% | GABC higher |
| ROA FY2025, SEC XBRL | +1.3% | -16.9% | GABC higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-09-30 | n/a | 0.56 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +37.8% | +8.3% | GABC higher |
| Revenue CAGR (3y) SEC XBRL | +20.6% | +6.8% | GABC higher |
| Dividend yield as of 2026-09-03 | 2.53% | n/a | |
| Dividend streak (yrs) SEC XBRL | 17 | 0 | GABC higher |
| Beta as of 2026-09-03 | 0.56 | 1.34 | |
| 1-year return as of 2026-10-30 close | +26.1% | +2.6% | GABC higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.